JP2022506445A5 - - Google Patents

Info

Publication number
JP2022506445A5
JP2022506445A5 JP2021523833A JP2021523833A JP2022506445A5 JP 2022506445 A5 JP2022506445 A5 JP 2022506445A5 JP 2021523833 A JP2021523833 A JP 2021523833A JP 2021523833 A JP2021523833 A JP 2021523833A JP 2022506445 A5 JP2022506445 A5 JP 2022506445A5
Authority
JP
Japan
Prior art keywords
substituted
groups
alkyl
independently
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021523833A
Other languages
English (en)
Japanese (ja)
Other versions
JP7489381B2 (ja
JP2022506445A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/058268 external-priority patent/WO2020092196A1/en
Publication of JP2022506445A publication Critical patent/JP2022506445A/ja
Publication of JP2022506445A5 publication Critical patent/JP2022506445A5/ja
Application granted granted Critical
Publication of JP7489381B2 publication Critical patent/JP7489381B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021523833A 2018-10-30 2019-10-28 Il-12、il-23および/またはifnアルファの調節に関連する疾患を治療するためのアミド置換ヘテロ環化合物 Active JP7489381B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862752414P 2018-10-30 2018-10-30
US62/752,414 2018-10-30
PCT/US2019/058268 WO2020092196A1 (en) 2018-10-30 2019-10-28 Amide-substituted heterocyclic compounds for the treatment of conditions related to the modulation of il-12, il-23 and/or ifn-alpha

Publications (3)

Publication Number Publication Date
JP2022506445A JP2022506445A (ja) 2022-01-17
JP2022506445A5 true JP2022506445A5 (cg-RX-API-DMAC7.html) 2022-11-07
JP7489381B2 JP7489381B2 (ja) 2024-05-23

Family

ID=68582450

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021523833A Active JP7489381B2 (ja) 2018-10-30 2019-10-28 Il-12、il-23および/またはifnアルファの調節に関連する疾患を治療するためのアミド置換ヘテロ環化合物

Country Status (13)

Country Link
US (1) US12240840B2 (cg-RX-API-DMAC7.html)
EP (1) EP3873892A1 (cg-RX-API-DMAC7.html)
JP (1) JP7489381B2 (cg-RX-API-DMAC7.html)
KR (1) KR102858043B1 (cg-RX-API-DMAC7.html)
CN (1) CN113227071B (cg-RX-API-DMAC7.html)
AU (1) AU2019373203B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021007861A2 (cg-RX-API-DMAC7.html)
CA (1) CA3118094A1 (cg-RX-API-DMAC7.html)
EA (1) EA202191142A1 (cg-RX-API-DMAC7.html)
IL (1) IL282840B2 (cg-RX-API-DMAC7.html)
MX (1) MX2021004562A (cg-RX-API-DMAC7.html)
SG (1) SG11202104307VA (cg-RX-API-DMAC7.html)
WO (1) WO2020092196A1 (cg-RX-API-DMAC7.html)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021195360A1 (en) * 2020-03-27 2021-09-30 Landos Biopharma, Inc. Plxdc2 ligands
KR20230004771A (ko) 2020-04-28 2023-01-06 브리스톨-마이어스 스큅 컴퍼니 Il-12, il-23 및/또는 ifn알파 조정제로서의 치환된 n-(메틸-d3)피리다진-3-카르복스아미드 또는 n-(메틸-d3)-니코틴아미드 화합물
KR102698413B1 (ko) 2020-05-05 2024-08-26 뉴베일런트, 아이엔씨. 헤테로방향족 거대환식 에터 화학치료제
WO2021226208A2 (en) 2020-05-05 2021-11-11 Nuvalent, Inc. Heteroaromatic macrocyclic ether chemotherapeutic agents
CN113773262B (zh) * 2020-06-09 2024-08-09 江苏先声药业有限公司 哒嗪类化合物
CN114057651B (zh) * 2020-07-31 2025-05-27 正大天晴药业集团股份有限公司 含酰胺基的tyk2抑制剂化合物
CN116547276A (zh) * 2020-12-08 2023-08-04 正大天晴药业集团股份有限公司 含酰胺基和杂环烷基的tyk2抑制剂化合物
CN122520625A (zh) 2020-12-22 2026-08-07 益方生物科技(上海)股份有限公司 杂芳基化合物及其制备方法和用途
CN114907326B (zh) * 2021-02-06 2025-02-18 正大天晴药业集团股份有限公司 含酰胺基和联环的tyk2抑制剂化合物
TWI925948B (zh) * 2021-02-06 2026-05-21 大陸商正大天晴藥業集團股份有限公司 含聯環的tyk2抑制劑化合物、藥物組合物及其用途
EP4308556A4 (en) * 2021-03-16 2025-02-19 Anrui Biomedical Technology (Guangzhou) Co., Ltd. Amino heteroaryl compounds and compositions
KR20240007242A (ko) * 2021-05-14 2024-01-16 브리스톨-마이어스 스큅 컴퍼니 치환된 헤테로시클릭 화합물
US20240317718A1 (en) * 2021-05-14 2024-09-26 Bristol-Myers Squibb Company Substituted heterocyclic compounds
KR20240008338A (ko) * 2021-05-14 2024-01-18 브리스톨-마이어스 스큅 컴퍼니 치환된 헤테로시클릭 화합물
WO2022253335A1 (zh) * 2021-06-02 2022-12-08 南京明德新药研发有限公司 含磺酰基的芳基类化合物及其应用
WO2022253333A1 (zh) * 2021-06-02 2022-12-08 南京明德新药研发有限公司 酰胺类化合物及其应用
CN115466289B (zh) * 2021-06-11 2026-07-03 爱科诺生物医药(苏州)有限公司 具有tyk2抑制活性的化合物,包含其的药物组合物,及其应用
CA3223641A1 (en) * 2021-06-22 2022-12-29 Wenyuan Qian Sulfoximine compound and use thereof
CN117794911A (zh) * 2021-07-15 2024-03-29 南京明德新药研发有限公司 含硫/磷的芳基类化合物及其应用
WO2023027948A1 (en) * 2021-08-21 2023-03-02 Relay Therapeutics, Inc. Jak2 inhibitors and methods of use thereof
TW202320768A (zh) 2021-10-01 2023-06-01 美商努法倫特公司 雜芳族大環醚化合物之固體形式、醫藥組成物及製備
KR20240111312A (ko) 2021-10-25 2024-07-16 카이메라 쎄라퓨틱스 인코포레이티드 Tyk2 분해제 및 이의 용도
TW202339749A (zh) 2021-12-16 2023-10-16 大陸商凌科藥業有限公司 Tyk2抑制劑及其組合物和方法
CN116283928A (zh) * 2021-12-20 2023-06-23 艾立康药业股份有限公司 一种哒嗪类化合物、其制备方法和应用
WO2023213308A1 (zh) * 2022-05-05 2023-11-09 苏州隆博泰药业有限公司 酰胺取代的杂环化合物及其医药用途
CN117263913A (zh) 2022-06-20 2023-12-22 益方生物科技(上海)股份有限公司 杂芳基化合物、固体形式、制备方法及其用途
JP2025523848A (ja) * 2022-07-14 2025-07-25 バイオジェン・エムエイ・インコーポレイテッド チロシンキナーゼ2阻害剤及びその使用
WO2024044486A1 (en) * 2022-08-22 2024-02-29 Ajax Therapeutics, Inc. Jak2 inhibitor compounds
CN120152968A (zh) * 2022-11-08 2025-06-13 百时美施贵宝公司 取代的杂环化合物
JP2025539787A (ja) * 2022-11-16 2025-12-09 ヴァーンウィ セラピューティクス,インコーポレイテッド Tyk2阻害剤
AU2023412260A1 (en) * 2022-12-22 2025-05-29 Usynova Pharmaceuticals Ltd. Salt form and crystal form of pyridine multi-substituted compound and preparation method therefor
WO2024174229A1 (en) * 2023-02-24 2024-08-29 Anrui Biomedical Technology (Guangzhou) Co., Ltd. Covalent binding compounds and compositions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2922841B8 (en) * 2012-11-08 2017-08-02 Bristol-Myers Squibb Company Alkyl-amide-substituted pyridyl compounds useful as modulators of il-12, il-23 and/or ifn alpha responses
HRP20220766T1 (hr) * 2012-11-08 2022-09-16 Bristol-Myers Squibb Company Amidom-supstituirani heterociklički spojevi korisni kao modulatori il-12, il-23 i/ili ifn alfa odgovora
AR094537A1 (es) * 2013-11-07 2015-08-12 Bristol Myers Squibb Co COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa
JP7485609B2 (ja) * 2018-03-22 2024-05-16 ブリストル-マイヤーズ スクイブ カンパニー IL-12、IL-23および/またはIFNα応答のモジュレーターとして有用なピリジン含有ヘテロ環式化合物
PE20250262A1 (es) * 2021-05-14 2025-01-29 Bristol Myers Squibb Co Compuestos heterociclicos sustituidos

Similar Documents

Publication Publication Date Title
RU2361868C2 (ru) Новые производные тиазола
US9763957B2 (en) Autotaxin inhibitors
RU2374230C2 (ru) Фенильные производные в качестве ppar агонистов
JP2018503661A5 (cg-RX-API-DMAC7.html)
JP2004502670A5 (cg-RX-API-DMAC7.html)
RU2010115574A (ru) Замещенные амиды, фармацевтическая композиция на их основе, способ лечения заболевания, чувствительного к btk, способ повышения чувствительности раковых клеток к химиотерапии, способ уменьшения ошибок при приеме лекарства и улучшения соблюдения схемы лечения, способ ингибирования гидролиза атф, способ определения присутствия btk в образце и способ ингибирования активности в-клеток
JP2007519695A5 (cg-RX-API-DMAC7.html)
JP2017214387A5 (cg-RX-API-DMAC7.html)
JP2010513283A (ja) 新規なオキサジアゾール化合物
JP2017193592A5 (cg-RX-API-DMAC7.html)
JP2005535586A5 (cg-RX-API-DMAC7.html)
RU2010146384A (ru) Пирролидиноновые активаторы глюкокиназы
JP2007509130A5 (cg-RX-API-DMAC7.html)
JP2008501673A5 (cg-RX-API-DMAC7.html)
RU2011108932A (ru) Карбазольные соединения и терапевтические применения соединений
RU2015111133A (ru) Ингибиторы тирозинкиназы брутона
RU2011116232A (ru) Пиразолопиридиновые производные как ингибиторы надфн-оксидазы
JP2018502906A5 (cg-RX-API-DMAC7.html)
RU2015132105A (ru) Азоловые производные бензола
RU2016111522A (ru) Фармацевтические соединения
JP2013529206A5 (cg-RX-API-DMAC7.html)
HRP20190943T1 (hr) Derivat 2-acilaminotiazola za uporabu u prevenciji ili liječenju bolesti mjehura/mokraćnog sustava
JP2024518556A5 (cg-RX-API-DMAC7.html)
HRP20200606T1 (hr) Derivati fenila kao agonisti kanabinoidnog receptora 2
JP2007211009A5 (cg-RX-API-DMAC7.html)